Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parexel Consulting Corporate VP Alberto Grignolo On Conducting Clinical Trials In China, India And Asia: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Parexel Consulting Corporate VP Alberto Grignolo recently spoke with PharmAsia News about Asia's evolving clinical trial environment - including the launch of U.S. FDA offices in Asia and the prospect of multinational companies conducting Phase I trials in India. Parexel works with life sciences companies to create clinical development strategies as well as Good Clinical Practices and Good Manufacturing Practices compliance.

You may also be interested in...



Sweeping Changes In India’s Clinical Trial Laws Could Allow Phase I MNC Studies Under Certain Circumstances

MUMBAI - Conducting clinical trials in India may get a little easier for multinational drug companies. That is because the much-awaited amendments to the contentious "Schedule Y" of India's Drug and Cosmetics Act have moved one step forward

U.S. FDA To Open Offices In China As Early As September; India Next

U.S. and China are close to finalizing plans to open U.S. FDA offices in China, and FDA could have "boots on the ground" as early as September, according to Murray Lumpkin, FDA's deputy commissioner for international and special Programs

Baxter’s War Games: Post-Heparin, Scientists Consider Supply Chain Threats

Part of Baxter's response to its heparin contamination fiasco has been to bring its scientists together to imagine ways counterfeiters could infiltrate its supply chain and how they would be countered.

UsernamePublicRestriction

Register

ID043835

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel